Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
At Oncodesign, each employee contributes to the success of the company’s mission through their commitment and adherence to our values! As we have developed and grown, Oncodesign has defined, adapted and implemented Human Resources policies consistent with our values and objectives.